3002.90.52.50/Anti-Hemophilic Factor VIII Concentrate/Canada

Anti-Hemophilic Factor VIII Concentrate from Canada

A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Provide coagulation activity units per vial and viral safety dossiers

• Ensure lyophilized form with reconstitution instructions for stability

• Avoid bulk plasma classification by specifying patient-ready dosing

Anti-Hemophilic Factor VIII Concentrate from Canada — Import Duty Rate | HTS 3002.90.52.50